PT-141 (Bremelanotide) vs GHRP-2
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Full details →GHRP-2
Growth Hormone Releasing Peptide 2 (GHRP-2) is considered one of the most potent GHRPs available. It provides strong GH release with moderate hunger increase compared to GHRP-6.
Full details →Side-by-Side Comparison
| Aspect | PT-141 (Bremelanotide) | GHRP-2 |
|---|---|---|
| Mechanism | PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system. | Binds to the ghrelin receptor (GHS-R) to stimulate GH release from the pituitary. Also has some direct effects on the hypothalamus. Causes less appetite increase than GHRP-6. |
| Typical Dosage | FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month. | Typical dosing: 100-300mcg administered 2-3 times daily. Often stacked with GHRH peptides for enhanced GH release. |
| Administration | Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols. | Subcutaneous injection on an empty stomach. Can be used at bedtime to enhance natural GH pulse during sleep. |
| Side Effects | Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur. | Moderate hunger increase, water retention, potential prolactin and cortisol elevation (less than GHRP-6), tingling sensations. |
| Best For |